Terms: = Bone cancer AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10 AND Treatment
28 results:
1. Myelodysplastic Neoplasms (MDS): The Current and Future treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract] [Full Text] [Related]
2. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
[TBL] [Abstract] [Full Text] [Related]
3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
4. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Haque T; Cadenas FL; Xicoy B; Alfonso-Pierola A; Platzbecker U; Avivi I; Brunner AM; Chromik J; Morillo D; Patel MR; Falantes J; Leitch HA; Germing U; Preis M; Lenox L; Lauring J; Brown RJ; Kalota A; Mehta J; Pastore F; Gu J; Mistry P; Valcárcel D
Leuk Res; 2023 Nov; 134():107390. PubMed ID: 37776843
[TBL] [Abstract] [Full Text] [Related]
5. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
6. Activation of distinct inflammatory pathways in subgroups of LR-MDS.
Schneider M; Rolfs C; Trumpp M; Winter S; Fischer L; Richter M; Menger V; Nenoff K; Grieb N; Metzeler KH; Kubasch AS; Sockel K; Thiede C; Wu J; Woo J; Brüderle A; Hofbauer LC; Lützner J; Roth A; Cross M; Platzbecker U
Leukemia; 2023 Aug; 37(8):1709-1718. PubMed ID: 37420006
[TBL] [Abstract] [Full Text] [Related]
7. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Klement P; Fiedler W; Gabdoulline R; Dallmann LK; Wienecke CP; Schiller J; Kandziora C; Teich K; Heida B; Büttner K; Brandes M; Funke C; Wichmann M; Othman B; Chromik J; Amberg S; Kebenko M; Schlipfenbacher V; Wilke AC; Modemann F; Janning M; Serve H; Bokemeyer C; Theile S; Deppermann U; Kranich AL; Ganser A; Thol F; Heuser M
Ann Hematol; 2023 Feb; 102(2):323-328. PubMed ID: 36576532
[TBL] [Abstract] [Full Text] [Related]
8. The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia.
Szelest M; Masternak M; Zając M; Chojnacki M; Skórka K; Zaleska J; Karczmarczyk A; Stasiak G; Wawrzyniak E; Kotkowska A; Siemieniuk-Ryś M; Purkot J; Subocz E; Cichocka E; Tomczak W; Zawirska D; Giannopoulos K
PLoS One; 2022; 17(10):e0276674. PubMed ID: 36282861
[TBL] [Abstract] [Full Text] [Related]
9. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M; Derkach A; Farnoud N; Bewersdorf JP; Robinson T; Famulare C; Cho C; Devlin S; Menghrajani K; Patel MA; Cai SF; Miles LA; Bowman RL; Geyer MB; Dunbar A; Epstein-Peterson ZD; McGovern E; Schulman J; Glass JL; Taylor J; Viny AD; Stein EM; Getta B; Arcila ME; Gao Q; Barker J; Shaffer BC; Papadopoulos EB; Gyurkocza B; Perales MA; Abdel-Wahab O; Levine RL; Giralt SA; Zhang Y; Xiao W; Pai N; Papaemmanuil E; Tallman MS; Roshal M; Goldberg AD
Am J Hematol; 2023 Jan; 98(1):79-89. PubMed ID: 36251406
[TBL] [Abstract] [Full Text] [Related]
10. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract] [Full Text] [Related]
11. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
Song J; Zhang H; Dong N; Zhang X; Hussaini M; Jain A; Moscinski L; Shain K; Baz R; Alsina M; Nishihori T; Zhang L
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e414-e426. PubMed ID: 34998786
[TBL] [Abstract] [Full Text] [Related]
12. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract] [Full Text] [Related]
13. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
[TBL] [Abstract] [Full Text] [Related]
14. sf3b1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
[TBL] [Abstract] [Full Text] [Related]
15. treatment of Acquired Sideroblastic Anemias.
Mangaonkar AA; Patnaik MM
Hematol Oncol Clin North Am; 2020 Apr; 34(2):401-420. PubMed ID: 32089219
[TBL] [Abstract] [Full Text] [Related]
16. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and
Pearson JM; Tan SF; Sharma A; Annageldiyev C; Fox TE; Abad JL; Fabrias G; Desai D; Amin S; Wang HG; Cabot MC; Claxton DF; Kester M; Feith DJ; Loughran TP
Mol Cancer Res; 2020 Mar; 18(3):352-363. PubMed ID: 31744877
[TBL] [Abstract] [Full Text] [Related]
17. Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases.
Mimiola E; Bomben R; De Matteis G; Perbellini O; Guglielmelli P; Bonifacio M; Parisi A; Gattei V; Zamò A; Mannelli F; García Montero AC; Zanotti R
Hematol Oncol; 2019 Dec; 37(5):628-633. PubMed ID: 31523839
[TBL] [Abstract] [Full Text] [Related]
18. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
Hu B; Patel KP; Chen HC; Wang X; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating M; Wierda WG
Br J Haematol; 2019 Nov; 187(3):307-318. PubMed ID: 31243771
[TBL] [Abstract] [Full Text] [Related]
19. Alteration of sf3b1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract] [Full Text] [Related]
20. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
Hu B; Patel KP; Chen HC; Wang X; Wang F; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating MJ; Wierda WG
Br J Haematol; 2019 Jun; 185(5):852-864. PubMed ID: 30924136
[TBL] [Abstract] [Full Text] [Related]
[Next]